The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

New-generation anti-obesity drug Wegovy, made by the same company that created Ozempic, is now available in France – but it ...

Metsera, a biotech focused on obesity treatments, came out of stealth only this year, and its lead drug is still in early ...

Some Rice University researchers have partnered with other institutions to continue bioelectrical implant treatment ...

The FDA cleared a drug-free capsule for weight management in adults with a BMI of 25-40, said maker Epitomee Medical. Once ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

The United States has passed peak obesity, according to new data, suggesting that the sweeping uptake of weight-loss drugs ...